Huasen Pharmaceuticals: The domestic production drug filing for Tralzopyr Hydrochloride Capsules is completed.

Huasen Pharmaceuticals announced that its product, Terazosin Hydrochloride Capsules, has completed the domestic drug filing process with the filing number Yubei 2026012831. Due to a change in the drug production license, the address of the manufacturing company listed in the drug registration approval documents has been updated. This drug is used to improve the urinary symptoms of patients with benign prostatic hyperplasia and to treat hypertension. It is recommended in multiple guidelines and listed in relevant drug catalogs. This filing will benefit the company by expanding production scale and enhancing competitiveness, but will not have a significant impact on performance in the short term. Investors are reminded to pay attention to risks.